Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

Sionna Therapeutics (SION) is back in focus after reporting topline results for its cystic fibrosis programs, including a Phase 2a proof of concept miss for SION-719 and supportive Phase 1 data for SION-451 combinations.

See our latest analysis for Sionna Therapeutics.

The Phase 2a miss for SION-719 triggered a sharp reset in sentiment, with Sionna Therapeutics' share price down 86.8% over the past week and 84.1% year to date. The 1-year total shareholder return has declined 70.1%, indicating pressure on both short and longer term performance.

If you are reviewing Sionna's cystic fibrosis update and thinking about what else is moving in healthcare, it can be useful to compare with other specialised opportunities through the 43 healthcare AI stocks

After such a sharp repricing in Sionna Therapeutics, some investors will see a beaten down biotech and others a value trap. Is it more sensible to step in after this move or wait for clearer valuation support next?

Preferred Price-to-Book of 1.1x: Is it justified?

The sharp reset in Sionna Therapeutics after its cystic fibrosis update sits against a valuation picture that looks very different to its peers. On a P/B basis, the stock is currently assessed as inexpensive relative to both similar companies and the broader US Biotechs group.

The preferred multiple here is the price to book ratio, which compares Sionna Therapeutics' market value to its net assets on the balance sheet. SION trades at a P/B of 1.1x, while the peer group average is 6.6x, suggesting the market is pricing its equity at a much lower level than comparable companies.

For a clinical stage biotech with minimal revenue and ongoing losses, book value is often a proxy for the cash and R&D platform that investors are paying for. A P/B of 1.1x versus a 6.6x peer average represents a steep discount, which indicates that expectations embedded in Sionna Therapeutics' share price are more cautious than for many sector peers with higher multiples.

Compared with the wider US Biotechs industry, where the average P/B stands at 2.4x, Sionna Therapeutics still trades on a materially lower multiple. The gap to both direct peers and the industry suggests a meaningful valuation disconnect rather than a marginal difference in pricing.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 1.1x (UNDERVALUED)